Metastasis is the process by which cancer cells spread from their original site and establish malignant growths elsewhere in the body. A secondary tumor produced by this process is called a metastasis; multiple secondary tumors are metastases. The secondary growth retains the identity of the cancer from which it arose: breast cancer that spreads to the liver remains metastatic breast cancer, not primary liver cancer. Metastasis is distinct from direct extension into neighboring tissue, although both are forms of cancer spread.
The formation of metastases requires cancer cells to overcome several biological barriers, including escape from the primary tumor, transport through the body, survival in unfamiliar tissue, and sustained growth at a distant site. These events depend on interactions among malignant cells, blood and lymphatic vessels, supporting tissue, and the immune system. Dissemination does not inevitably produce a detectable tumor: many displaced cells die, while others persist in a dormant state.
Metastatic disease is responsible for much of the serious illness and mortality associated with solid cancers. Its behavior varies considerably by cancer type, molecular characteristics, involved organs, and treatment responsiveness. Understanding metastasis therefore requires both a biological account of how tumors spread and a clinical account of how secondary disease is identified, classified, and treated.
Definition, classification, and clinical significance
A primary tumor is the malignant growth at the site where a cancer originated. A metastasis develops when cells derived from that cancer establish a separate malignant deposit. This distinction is based on cellular origin rather than location alone. For example, an adenocarcinoma in the lung may be a primary lung cancer or a metastasis from the colon, and distinguishing these possibilities can change both staging and treatment. The interpretation draws on the distribution of disease, microscopic appearance, molecular findings, and the patient's clinical history.
Local invasion, regional spread, and distant metastasis describe related but different patterns. Local invasion is continuous growth into adjacent structures. Regional spread commonly includes involvement of nearby lymph nodes, although the definition of “regional” depends on the primary cancer. Distant metastasis generally means spread to an organ or lymph-node group outside the regional drainage territory. A lymph-node deposit can therefore be regional in one anatomical setting and distant in another. Whether deposits on a body-cavity surface count as distant disease also depends on the cancer-specific staging system.
For many solid tumors, the TNM staging system describes the primary tumor with T, regional nodes with N, and distant metastasis with M. M0 indicates no identified distant metastasis under the relevant staging assessment, whereas M1 indicates its presence. Many, but not all, cancers with distant metastasis are classified as stage IV. Staging rules are not interchangeable across cancer types, and some diseases use other systems. A negative metastatic assessment means that spread has not been detected; it does not prove that no disseminated malignant cells exist.
Metastases may be synchronous, meaning present when the primary cancer is diagnosed, or metachronous, meaning detected later. Disease recurring at the original site is a local recurrence; disease appearing at a distant site is a distant recurrence. Some patients present with metastases before the original site can be identified. This presentation is termed cancer of unknown primary, a clinical category that includes several distinct biological situations rather than a single disease.
The concept applies most directly to solid tumors. Leukemias usually involve blood-forming tissues and blood from the outset, so their systemic distribution is not normally described as metastasis. Lymphomas have their own patterns of dissemination and staging. Conversely, some solid tumors can become life-threatening through local destruction without producing distant deposits. Metastatic status is therefore a major clinical descriptor, but it does not by itself capture every form of malignant behavior.
Routes of dissemination
Cancer cells spread principally through lymphatic channels, blood vessels, or body cavities. These routes overlap rather than forming mutually exclusive pathways. A tumor may invade both lymphatic and blood vessels, and cells entering lymph eventually return to the venous circulation. The architecture of the primary organ, the vessels available to the tumor, and the biological properties of its cells all influence which routes predominate.
Lymphatic dissemination begins when malignant cells enter vessels of the lymphatic system. Many initial lymphatic vessels have thin walls and relatively permissive junctions, allowing fluid and cells to enter from surrounding tissue. Tumor cells may be carried to draining nodes, where they can die, persist, or proliferate. The first draining node or group of nodes is called the sentinel node. In selected cancers, particularly breast cancer and melanoma, sentinel lymph-node biopsy provides information about regional spread. A positive node is clinically informative, but it does not establish that every subsequent distant metastasis must have passed through that node.
Hematogenous dissemination occurs when cancer cells enter the bloodstream. Venous drainage helps explain several common patterns. Much of the blood leaving the colon passes through the portal circulation to the liver, making the liver a frequent metastatic site in colorectal cancer. Blood from many other tissues reaches the lungs through the right side of the heart. Nevertheless, circulation alone cannot explain metastatic distribution: many cells pass through organs without establishing tumors, and some cancers preferentially colonize sites that are not simply the first capillary bed encountered.
Transcoelomic spread involves shedding into a body cavity followed by implantation on its surfaces. Ovarian carcinoma often spreads across the peritoneal cavity, producing deposits on the peritoneum and omentum. Tumor cells and associated vascular changes can contribute to ascites, an accumulation of abdominal fluid. Pleural dissemination can similarly produce malignant pleural effusions. These patterns differ mechanically from a cell crossing a distant blood-vessel wall, although they still require survival away from the original tumor and successful growth at a new surface.
Some tumors disseminate through cerebrospinal fluid, producing deposits along the surfaces of the brain, spinal cord, or nerve roots. This is called leptomeningeal dissemination when the involved compartment is the leptomeninges and associated cerebrospinal-fluid spaces. It can occur with systemic cancers and with certain primary central nervous system tumors. Perineural invasion, by contrast, refers to tumor growth along or around nerves and is often a form of local or regional extension rather than distant metastasis. These distinctions matter because anatomical routes determine where disease appears and which diagnostic methods can detect it.
Escape from the primary tumor and survival in transit
The metastatic cascade begins with the ability of cancer cells to leave their original tissue environment. In epithelial cancers, malignant cells must breach or bypass the basement membrane and move through surrounding connective tissue. The extracellular matrix is not merely a passive barrier: its collagen fibers, adhesive molecules, and stiffness influence movement and signaling. Cancer cells and nearby stromal cells can remodel it through mechanical forces and enzymes, including matrix metalloproteinases. Some cells migrate individually; others advance as coordinated groups while retaining connections to neighboring tumor cells.
One important biological framework is the epithelial–mesenchymal transition, or EMT. In experimental systems, this program can reduce epithelial adhesion and increase motility, invasiveness, and resistance to stress. Transcription factors such as SNAIL, TWIST, and ZEB proteins participate in these changes. However, metastasis is not governed by a universal switch from a purely epithelial to a purely mesenchymal state. Human tumors often contain intermediate states, and some metastatic cells travel collectively while preserving epithelial features. Cellular plasticity—the capacity to change state—may be more important than permanent adoption of one phenotype.
Entry into a blood vessel is called intravasation. It can occur where tumor-associated vessels are structurally abnormal or where interactions among malignant cells, macrophages, and endothelial cells promote passage through the vessel wall. Poor oxygenation can activate pathways involving hypoxia-inducible factors, altering cell movement, metabolism, and production of factors such as vascular endothelial growth factor. These changes link the local tumor environment to dissemination, but no single pathway is required in every cancer.
Once in the bloodstream, circulating tumor cells encounter mechanical stress, immune attack, and the loss of attachment-dependent survival signals. Detachment can trigger a form of programmed cell death called anoikis. Cells that resist these pressures may circulate individually or as clusters. Clusters can include several malignant cells and sometimes associated nonmalignant cells. Experimental and clinical observations indicate that clustered dissemination can have important metastatic potential, although its contribution differs among tumors.
Platelets can adhere to circulating cancer cells, participate in microemboli, and modify interactions with immune cells and blood-vessel walls. This connects dissemination to blood coagulation and helps explain part of the biological association between cancer and thrombosis. Yet survival in circulation is only an intermediate achievement. Most cells released from a tumor do not become clinically apparent metastases. Losses occur at multiple stages, and even cells that reach a distant organ may fail to survive or grow there. The metastatic cascade is therefore an inefficient process at the level of individual cells, despite its major consequences for the patient.
Organ preference and the metastatic microenvironment
Metastatic cancers show organ tropism: a nonrandom tendency to establish tumors in particular tissues. Breast cancer commonly spreads to bone, liver, lung, and brain; prostate cancer has a marked tendency to involve bone; and colorectal cancer frequently involves the liver. These are population-level patterns, not fixed rules for individual tumors. Organ preference reflects both the route of cell delivery and the compatibility between cancer cells and the tissue they encounter.
After arresting in a distant vessel, a cell may cross the endothelial lining through a process called extravasation. Some cells become mechanically trapped in narrow capillaries, whereas others adhere through molecular interactions. The blood–brain barrier presents specialized obstacles to entry into the brain, including tight endothelial junctions and interactions with supporting cells. Brain metastases can alter this barrier, but the resulting blood–tumor barrier remains heterogeneous. This affects both tumor biology and the access of some drugs to individual lesions.
Successful colonization depends on the metastatic microenvironment: fibroblasts, immune cells, vascular cells, matrix, signaling molecules, and local nutrients. A tissue can restrain malignant growth or support it. Cancer cells may recruit blood vessels through angiogenesis, but some metastases instead grow along and use pre-existing vessels, a process known as vessel co-option. Signals from stromal cells can promote survival, change metabolism, or suppress antitumor immunity. Consequently, the same cancer cell population may behave differently in different organs.
Bone illustrates a particularly well-studied interaction. Normal bone maintenance depends on coordinated activity by bone-resorbing osteoclasts and bone-forming osteoblasts. In osteolytic metastases, tumor-derived signals can increase osteoclast activity. Resorption releases growth factors stored in bone matrix, which can further support tumor growth, creating a reinforcing cycle. Breast cancer often produces osteolytic or mixed lesions. Prostate cancer commonly produces predominantly osteoblastic lesions, although increased bone formation does not mean the resulting bone is structurally normal, and resorption can also be active.
The primary tumor can also alter distant tissues before detectable malignant colonization. The term premetastatic niche describes such preparatory changes, including matrix remodeling, altered vascular permeability, and recruitment of particular immune or bone-marrow-derived cells. Tumor-secreted factors and extracellular vesicles have been implicated in experimental models. The extent to which particular niche mechanisms operate in individual human cancers is less completely defined. This framework complements rather than replaces anatomical explanations: where cells are delivered, whether they survive, and whether the destination supports growth all contribute to the final distribution of metastases.
Dormancy, evolution, and metastatic colonization
The arrival of a malignant cell in a distant organ is not equivalent to the formation of a growing secondary tumor. Disseminated cells may die, remain as isolated cells, form microscopic deposits, or progress to overt metastases. Establishing sustained growth—metastatic colonization—is often a major biological bottleneck. A cell must obtain survival signals, adapt to local nutrients and physical conditions, avoid immune elimination, and maintain enough proliferation to outweigh cell loss.
Tumor dormancy encompasses more than one state. Cellular dormancy describes individual cells with little or no division, often associated with reversible withdrawal from the active cell cycle. Tumor-mass dormancy describes a small population whose proliferation is balanced by cell death or constrained by factors such as inadequate vascular support. Immune control can also maintain a population below the threshold of clinically detectable growth. These states are not necessarily permanent, and they are difficult to distinguish directly in patients.
Dormancy helps explain why distant recurrence can occur years after apparently successful treatment of the primary tumor. Late recurrence is particularly important in some hormone-receptor-positive breast cancers and in prostate cancer. However, a long interval does not establish one unique mechanism: slow continuous growth below imaging thresholds can resemble a period of true quiescence. Tissue sampling is limited, and repeated observation of the same dormant human cell population is rarely possible.
Cancer evolves through heritable variation and selection. A primary tumor contains subpopulations with different mutations, patterns of gene expression, and capacities for survival. Metastases usually share ancestral alterations with the primary cancer but may acquire or select additional changes. Studies comparing tumor genomes have supported different evolutionary histories: some metastases arise from relatively late branches of the primary tumor, whereas in other settings dissemination occurs earlier and is followed by prolonged parallel evolution. There is no single timetable that applies to all cancers.
Metastatic spread can also be more complex than one primary tumor independently seeding every secondary site. Genomic reconstructions have found evidence consistent with metastasis-to-metastasis dissemination and, in some settings, seeding by multiple clones. Treatment adds another selective pressure: drug-sensitive populations may shrink while resistant populations persist or expand. Differences among lesions can therefore reflect both their separate evolutionary histories and their distinct environments. A sample from one site is informative, but it may not represent every malignant population in the body. These dynamics explain why metastatic disease can change its behavior and molecular profile over time.
Clinical presentation, detection, and confirmation
Metastatic disease may be discovered because it causes symptoms, because staging examinations reveal it, or during investigation of a later recurrence. Some deposits remain asymptomatic for substantial periods. Manifestations depend on location and burden rather than on a single characteristic “metastatic” symptom. Bone involvement can cause pain, fractures, or compression of the spinal cord. Brain lesions can produce seizures, focal neurological deficits, or headache. Pulmonary and pleural disease can contribute to cough or shortness of breath, while extensive liver involvement can impair hepatic function.
Imaging establishes the anatomical distribution of suspected disease. Computed tomography is widely used to assess the chest, abdomen, and pelvis. Magnetic resonance imaging provides detailed evaluation of the brain, spine, marrow, and selected soft tissues. Bone scintigraphy detects patterns of bone turnover rather than cancer cells themselves. Positron emission tomography, often combined with CT, uses radiotracers to reveal selected metabolic or molecular processes. Fluorodeoxyglucose uptake is useful in many cancers, but it is not specific for malignancy, and some tumors have low uptake.
Imaging findings require interpretation in context. Infection, inflammation, benign nodules, healing fractures, and other conditions can resemble metastases. Conversely, microscopic deposits and some small lesions remain below the detection limits of imaging. A new lesion in a person with cancer is therefore not automatically a metastasis; it may represent an unrelated benign process or a second primary malignancy. The likelihood depends on its appearance, location, timing, and the known behavior of the original cancer.
A biopsy can establish the nature of a lesion and provide material for histopathological and molecular analysis. Pathologists compare cellular architecture and immunohistochemical markers with those expected from possible primary sites. Panels of markers are generally more informative than a single stain. Molecular testing can identify clinically relevant alterations or help clarify relationships between tumors, but the interpretation remains integrated with morphology and clinical information. Not every suspected metastatic deposit is sampled; confirmation practices vary with the clinical setting and whether tissue findings would change classification or management.
Blood-based tests provide complementary information. Established tumor markers can help monitor selected cancers, but most lack sufficient sensitivity and specificity to diagnose metastasis independently. Liquid biopsy methods examine tumor-derived material such as circulating tumor DNA or circulating tumor cells. These approaches can identify certain molecular alterations and track changing disease signals. A negative result does not exclude metastatic disease, because shedding varies with tumor size, anatomical site, and biology. Detection of a molecular signal, anatomical localization of disease, and proof of a viable growing metastasis are related but distinct findings.
Treatment of established metastatic disease
Treatment depends on the primary cancer, its molecular features, the sites and extent of spread, previous therapy, and the patient's clinical condition. Because metastasis often involves deposits at several locations or microscopic disease beyond visible lesions, systemic treatment has a central role. Nevertheless, metastatic cancer is not a single therapeutic category. Some malignancies are highly treatment-sensitive and can be cured despite dissemination, whereas others are managed through successive treatments that reduce disease burden, delay progression, or relieve symptoms.
Chemotherapy acts through mechanisms such as damage to DNA or disruption of cell division. Endocrine treatments interfere with hormone production or signaling in susceptible tumors, including many breast and prostate cancers. Targeted treatments inhibit specific molecular dependencies. Examples include HER2-directed agents in HER2-positive breast cancer and inhibitors directed at particular EGFR or ALK alterations in lung cancer. Molecular selection is important: the presence of a potentially targetable pathway in cancer generally does not mean that every drug affecting that pathway will be effective.
Cancer immunotherapy can produce durable responses in some metastatic cancers. Immune checkpoint inhibitors alter inhibitory signaling that can limit antitumor T-cell activity. Their effectiveness varies by cancer type and biological context, and some tumors show primary or acquired resistance. Other drug classes include antibody–drug conjugates, which combine an antibody-based targeting component with a cytotoxic payload. Treatment selection may use validated biomarkers, but no biomarker perfectly predicts benefit across all settings.
Local treatments retain important roles. Surgery can remove selected deposits, while radiation therapy can control lesions or relieve symptoms at particular sites. Thermal ablation and other image-guided procedures are used in defined circumstances. Long-term disease control, and sometimes cure, is possible after treatment of selected colorectal liver metastases. Stereotactic radiation is used for some brain and extracranial metastases. These outcomes depend heavily on cancer type and patient selection; they cannot be generalized to every situation in which only a few lesions are visible.
The term oligometastatic disease describes a limited metastatic state in which comprehensive treatment of visible lesions may be feasible. Definitions differ by cancer and study, and lesion count alone does not establish a distinct underlying biology. “Oligoprogression” describes limited progression at a few sites while other disease remains controlled. Trials evaluating local treatment must separate its effects from favorable patient selection. Alongside tumor-directed treatment, palliative care addresses symptoms, function, communication, and quality of life; it can be delivered concurrently with active anticancer therapy rather than only at the end of life.
Prognosis, response assessment, and prevention of recurrence
Prognosis in metastatic cancer varies substantially. Relevant factors include tissue of origin, molecular subtype, treatment sensitivity, organ involvement, disease burden, and functional status. A small number of metastatic deposits may have a different outlook from rapidly progressive involvement of several organs, but anatomical extent is only one dimension. Certain molecularly defined tumors respond for prolonged periods to effective systemic treatment, while some apparently limited cancers behave aggressively. A single survival estimate for all metastatic cancers would conceal clinically important differences.
Population survival statistics describe groups, not the future course of an individual patient. Their interpretation also depends on the starting point, such as initial diagnosis or detection of metastasis, and on whether the measure is overall survival, cancer-specific survival, or relative survival. Outcomes observed in a clinical trial may differ from those in a broader population because eligibility criteria and treatment access differ. Comparisons across periods can also be affected by improvements in detection: finding smaller deposits earlier can lengthen measured survival from metastatic diagnosis without necessarily changing the date of death.
Treatment response is commonly assessed through imaging, symptoms, examination, and relevant laboratory measurements. Standardized systems such as RECIST use defined measurements of selected lesions to classify response or progression. These systems improve consistency but have limitations. A bone lesion may become more sclerotic during healing without a straightforward reduction in size. Immunotherapy can occasionally produce atypical patterns such as an initial increase in apparent disease followed by reduction. Changes in tumor markers can be informative, but they do not always parallel changes in every metastatic site.
Preventing distant recurrence is one purpose of adjuvant systemic therapy given after definitive treatment of a primary tumor. Such therapy targets residual malignant cells that may be present despite the absence of detectable metastases. Neoadjuvant treatment, given before surgery or other definitive local treatment, can also address systemic disease while treating the primary tumor. Evidence for benefit is cancer- and regimen-specific and is established through studies measuring outcomes such as recurrence and survival. Detecting residual tumor-derived DNA after treatment is an active area of investigation, but a test's prognostic value does not automatically establish that changing treatment on the basis of that test improves outcomes.
Metastatic complications can influence prognosis independently of measured tumor size. Spinal-cord compression, pathological fractures, organ failure, and malignant fluid accumulations can cause substantial disability. Cancer and its treatments can also contribute to malnutrition, anemia, fatigue, and thromboembolic disease. These effects illustrate why response assessment includes clinical function and symptoms rather than imaging alone. A treatment can have meaningful effects on disease burden while also causing toxicity, and formal studies increasingly include patient-reported outcomes alongside progression and survival endpoints.
Historical development and research methods
The understanding of metastasis developed from anatomical observation into an experimental and molecular science. In the nineteenth century, clinicians and pathologists recognized recurring patterns of secondary tumor distribution, but mechanical transport did not adequately explain why particular cancers favored particular organs. In 1889, the English surgeon Stephen Paget analyzed breast-cancer postmortem records and proposed the “seed and soil” hypothesis: cancer cells were the seeds, while receptive tissues supplied the soil. His account emphasized that secondary growth depended on compatibility between the two.
In 1928, the American pathologist James Ewing emphasized circulatory anatomy and mechanical factors in metastatic distribution. Later work showed that anatomical delivery and tissue compatibility are complementary explanations rather than mutually exclusive theories. Blood flow influences where tumor cells arrive; local conditions influence whether they survive and form growing lesions. This combined view remains fundamental to contemporary descriptions of organ tropism.
Experimental studies in the twentieth century made metastasis a process that could be dissected into stages. In 1973, Isaiah Fidler reported selection of melanoma cell populations with enhanced metastatic behavior in mice. Fidler and Margaret Kripke's subsequent work supported the existence of tumor-cell subpopulations differing in metastatic capacity. These experiments helped establish tumor heterogeneity and selection as central concepts. Later studies added the importance of reversible cell states, immune interactions, and organ-specific adaptation, extending the explanation beyond a fixed, exclusively genetic “metastatic cell” phenotype.
Different research models answer different questions. Injecting tumor cells into a vein tests survival in circulation and colonization of organs reached by that route, but bypasses local invasion and intravasation. Orthotopic models place tumors in the organ of origin and can reproduce more of the spontaneous cascade. Genetically engineered animals allow tumors to arise in defined tissues with selected alterations. Patient-derived models retain some features of human tumors, although transplantation, host immunity, and laboratory selection can change their behavior. No single model reproduces all aspects of human metastatic disease.
Modern approaches include intravital microscopy, lineage tracing, genomic comparison of multiple tumor sites, single-cell analysis, and spatial profiling. These methods can reveal cell movement, reconstruct ancestry, and map interactions within metastatic tissue. Their limitations differ: an evolutionary tree inferred from sampled lesions cannot recover every unsampled population, and a molecular profile is often a snapshot rather than a continuous record. Major research questions include how dormant cells resume growth, how immune control fails at different organs, and why some disseminated populations remain sensitive to treatment while others become resistant. Testing interventions against these processes requires endpoints that distinguish reduced cell dissemination, delayed detectable recurrence, and improved clinical outcomes.